Resource Type

Journal Article 35

Year

2023 1

2022 2

2021 4

2020 4

2019 7

2018 1

2017 1

2016 1

2015 2

2014 1

2013 1

2009 3

2008 1

2007 1

open ︾

Keywords

Efficacy 7

Safety 4

COVID-19 2

Coronavirus disease 2019 2

Metabolomics 2

SARS-CoV-2 2

Triazavirin 2

efficacy 2

safety 2

3-DR-IUD 1

ALK fusion 1

Neospora caninum 1

Acanthaceae 1

Adeno-associated virus 1

Andrographis paniculata 1

Andrographolide 1

Antibody–drug conjugate 1

Antigen 1

Bioactive compound 1

open ︾

Search scope:

排序： Display mode:

A review of the safety and efficacy of current COVID-19 vaccines

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 39-55 doi: 10.1007/s11684-021-0893-y

Abstract: This study reviewed the efficacy/effectiveness, immunogenicity, and safety profile of the 12 most progressedOverall, most of the current vaccines have shown safety and efficacy/effectiveness during actual clinical

Keywords： COVID-19     SARS-CoV-2     vaccine     safety     efficacy     effectiveness     immunogenicity    

HTML PDF Collect
Share

Heterogeneous influence of individuals’ behavior on mask efficacy in gathering environments

Frontiers of Engineering Management   Pages 550-562 doi: 10.1007/s42524-022-0193-5

Abstract: Although masks can slow down the spread of viruses, their efficacy in gathering environments involvingThe heterogeneity of individuals can cause mask efficacy in a specific gathering environment to be differentfrom the baseline efficacy in general society.This study contributes to the accurate evaluation of mask efficacy in various gathering environments

Keywords： COVID-19     masks     behavioral heterogeneity     asymptomatic infection    

HTML PDF Collect
Share

Retrospective study of the efficacy and complication of thoracoabdominal incision for nephrectomy: a

Minggen YANG, Xiaokun ZHAO

Frontiers of Medicine 2009, Volume 3, Issue 2,   Pages 191-196 doi: 10.1007/s11684-009-0026-5

Abstract: Efficacy and complication was comparable for thoracoabdominal and flank incisions in terms of incisional

Keywords： surgery     renal tumors     nephrectomy    

HTML PDF Collect
Share

Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary

Jiangyi Zhu, Yongquan Shi, Xinmin Zhou, Zengshan Li, Xiaofeng Huang, Zheyi Han, Jianhong Wang, Ruian Wang, Jie Ding, Kaichun Wu, Ying Han, Daiming Fan

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 255-263 doi: 10.1007/s11684-012-0227-1

Abstract:

The efficacy of ursodeoxycholic acid (UDCA) on long-term outcome of primary biliary cirrhosis (PBC

Keywords： primary biliary cirrhosis     ursodeoxycholic acid     Chinese     biochemical response     therapeutic efficacy    

HTML PDF Collect
Share

Potential unreliability of variant allele frequency in the efficacy prediction of targeted therapy in

Frontiers of Medicine doi: 10.1007/s11684-022-0946-x

Abstract: However, the clinical efficacy is highly variable.variant allele frequencies (VAFs) of ALK fusions can help assess ITH and predict targeted therapy efficacystrong>%, or 20%), the association of ALK subclonality with crizotinib efficacydetermined by hybrid capture-based NGS is probably unreliable for ITH assessment and targeted therapy efficacy

Keywords： ALK fusion     next-generation sequencing     fluorescence in situ hybridization     immunohistochemistry     variant allele frequency     intratumoral heterogeneity     targeted therapy    

HTML PDF Collect
Share

Protective efficacy of vaccination with NcMIC3 and NcMIC8 against

Taotao ZHANG, Xiao ZHANG, Qun LIU, Jianhai XU, Jing LIU

Frontiers of Agricultural Science and Engineering 2019, Volume 6, Issue 2,   Pages 188-196 doi: 10.15302/J-FASE-2019253

Abstract: In this study, we evaluated the protective efficacy of recombinant proteins and DNA vaccines of NcMIC3

Keywords： NcMIC3     NcMIC8     Neospora caninum     vaccination    

HTML PDF Collect
Share

A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against

PAN Jiangang, ZHOU Xing, CHEN Zhiguang, HAN Ruifa

Frontiers of Medicine 2008, Volume 2, Issue 3,   Pages 259-263 doi: 10.1007/s11684-008-0049-3

Abstract: Meta-analysis was used to determine whether maintenance intravesical bacillus Calmette-Guerin (BCG) could reduce recurrence after transurethral resection of tumor 1 grade 3 (T1G3) superficial bladder cancer. All available published data of randomized clinical trials comparing transurethral resection plus intravesical BCG to either resection alone or resection plus another treatment on the treatment results in patients with superficial bladder cancer of T1G3 were selected for analysis. Both the fixed effects model and random effects model were applied, and the odds ratio () with its 95% confidence interval (CI) was used as the effect size estimate. Sensitivity analysis and publication bias determination were performed by funnel plots and comparing s of different models. Within the follow-up period, 375 of 915 (41.0%) BCG-treated patients and 332 of 733 (45.3%) non-BCG-treated patients developed tumor recurrence. In the combined results, a statistically significant difference in the s for tumor recurrence between the two treatment groups was found (randomized model combined effect 0.58, 95% CI 0.41 to 0.83, = 0.003). The stratified meta-analysis did not show any statistically significant confounding effects on the results when stratified by BCG strains. The randomized model combined effect of Pasteur F and other strains were 0.50 (95% CI 0.26 to 0.95, = 0.04) and 0.63 (95% CI 0.40 to 0.99, = 0.04), respectively. Therefore, we came to the conclusion that adjuvant maintenance instillation BCG combined with transurethral resection of bladder tumor (TURBT) is an effective conservative treatment for preventing recurrence of T1G3 bladder cancer.
HTML PDF Collect
Share

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 726-745 doi: 10.1007/s11684-020-0746-0

Abstract: Chimeric antigen receptor (CAR) T cells have been indicated effective in treating B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma and have shown encouraging results in preclinical and clinical studies. However, CAR T cells have achieved minimal success against solid malignancies because of the additional obstacles of their insufficient migration into tumors and poor amplification and persistence, in addition to antigen-negative relapse and an immunosuppressive microenvironment. Various preclinical studies are exploring strategies to overcome the above challenges. Mobilization of endogenous immune cells is also necessary for CAR T cells to obtain their optimal therapeutic effect given the importance of the innate immune responses in the elimination of malignant tumors. In this review, we focus on the recent advances in the engineering of CAR T cell therapies to restore the immune response in solid malignancies, especially with CAR T cells acting as cellular carriers to deliver immunomodulators to tumors to mobilize the endogenous immune response. We also explored the sensitizing effects of conventional treatment approaches, such as chemotherapy and radiotherapy, on CAR T cell therapy. Finally, we discuss the combination of CAR T cells with biomaterials or oncolytic viruses to enhance the anti-tumor outcomes of CAR T cell therapies in solid tumors.

Keywords： CAR T cells     immunoregulatory molecules     endogenous immune response     solid malignancies    

HTML PDF Collect
Share

Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patients

Frontiers of Medicine   Pages 736-744 doi: 10.1007/s11684-021-0870-5

Abstract: A pilot study on TCM syndrome differentiation can evaluate the clinical efficacy and safety of TCM and

Keywords： pneumoconiosis     randomized controlled trials     traditional Chinese medicine    

HTML PDF Collect
Share

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal

Frontiers of Medicine doi: 10.1007/s11684-022-0945-y

Abstract: The abnormal activation of HER family kinase activity is closely related to the development of human malignancies. In this study, we used HER kinases as targets for the treatment of nasopharyngeal carcinoma (NPC) and explored the anti-tumor effects of the novel pan-HER inhibitor HM781-36B, alone or in combination with cisplatin. We found that HER family proteins were positively expressed in tumor tissues of some NPC patients, and the high levels of those proteins were significantly related to poor prognosis. HM781-36B inhibited NPC in vitro and in vivo. HM781-36B exerted synergistic effects with cisplatin on inhibiting proliferation and promoting apoptosis of NPC cells. In NPC xenograft models in nude mice, HM781-36B and cisplatin synergistically inhibited tumor growth. Downregulating the activity of HER family proteins and their downstream signaling pathways and regulating tumor microenvironment may explain the synergistic anti-tumor effects of HM781-36B and cisplatin. In conclusion, our study provides evidence for HER family proteins as prognostic biomarkers and potential therapeutic targets for NPC. The pan-HER inhibitor HM781-36B alone or in combination with cisplatin represents promising therapeutic effects for the treatment of NPC patients, which provides a new idea for the comprehensive treatment of NPC.

Keywords： epidermal growth factor receptor     ErbB receptors     HM781-36B     nasopharyngeal carcinoma     molecular targeted therapy     cisplatin    

HTML PDF Collect
Share

Experimental study on the efficacy of Fuganling granula on protecting against immunological hepatic injury

Yanli LIU, Rong LIU, Cheng ZHEN, Quanfang GUO, Liping WU, Zhaoxi DING, Yushun BI, Zhiyu LIU

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 91-95 doi: 10.1007/s11684-009-0011-z

Abstract: To study the efficacy of Fuganling granula (FGL, 复肝灵颗粒) in treating mouse immunological hepatic injury

Keywords： Fuganling granula     immunological liver injury     bacille calmette guerin     lipopolysaccharide     mice    

HTML PDF Collect
Share

Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes

Frontiers of Medicine doi: 10.1007/s11684-022-0939-9

Abstract: To evaluate the safety and efficacy of neoadjuvant radiohormonal therapy for oligometastatic prostate

Keywords： neoadjuvant     radiotherapy     oligometastatic     prostate cancer     radical prostatectomy    

HTML PDF Collect
Share

Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for

Huicong KANG, Xiaoyan LIU, Hu QI, Feng XU, Xiang LI, Yuan WANG, Zhiguang LIU, Suiqiang ZHU

Frontiers of Medicine 2009, Volume 3, Issue 2,   Pages 181-186 doi: 10.1007/s11684-009-0025-6

Abstract: The purpose of our research was to evaluate the efficacy, tolerance, and safety of oxcarbazepine (OXCWe observed the efficacy and safety in the first three months and the following three months respectively

Keywords： oxcarbazepine     partial epilepsy    

HTML PDF Collect
Share

Modified Therapeutic Antibodies: Improving Efficacy Review

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Engineering 2021, Volume 7, Issue 11,   Pages 1529-1540 doi: 10.1016/j.eng.2020.06.030

Abstract: half-life in circulation, effectiveness toward target cells and, ultimately, to achieve overall improved efficacy

Keywords： Therapeutic antibody     Modification     Efficacy     Antigen     Antibody–drug conjugate     Bispecific antibody    

HTML PDF Collect
Share

follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 344-353 doi: 10.1007/s11684-018-0639-7

Abstract: Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML). In 2007, a pivotal phase-2 study of dasatinib as second-line treatment was initiated in 140 Chinese CML patients. This report from the 4-year follow-up revealed that 73% of 59 patients in chronic phase (CML-CP) and 32% of 25 patients in accelerated phase (CML-AP) remained under treatment. The initial dosage of dasatinib for CML-CP and CML-AP patients were 100 mg once daily and 70 mg twice daily (total= 140 mg/day), respectively. The cumulative major cytogenetic response (MCyR) rate among patients with CML-CP was 66.1% (versus 50.8% at 18 months), and the median time to MCyR was 12.7 weeks. All CML-CP patients who achieved MCyR after a 4-year follow-up also achieved a complete cytogenetic response. The cumulative complete hematological response (CHR) rate among patients with CML-AP was 64% (16/25), with three CML-AP patients achieving CHR between 18 months and 4 years of follow-up; the median time to CHR was 16.4 weeks. The adverse event (AE) profile of dasatinib at 4 years was similar to that at 6 and 18 months. The most frequently reported AEs (any grade) included pleural effusion, headache, and myelosuppression. These long-term follow-up data continue to support dasatinib as a second-line treatment for Chinese patients with CML.

Keywords： chronic myeloid leukemia (CML)     dasatinib     tyrosine kinase inhibitor     long-term follow-up    

HTML PDF Collect
Share

Title Author Date Type Operation

A review of the safety and efficacy of current COVID-19 vaccines

Journal Article

Heterogeneous influence of individuals’ behavior on mask efficacy in gathering environments

Journal Article

Retrospective study of the efficacy and complication of thoracoabdominal incision for nephrectomy: a

Minggen YANG, Xiaokun ZHAO

Journal Article

Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary

Jiangyi Zhu, Yongquan Shi, Xinmin Zhou, Zengshan Li, Xiaofeng Huang, Zheyi Han, Jianhong Wang, Ruian Wang, Jie Ding, Kaichun Wu, Ying Han, Daiming Fan

Journal Article

Potential unreliability of variant allele frequency in the efficacy prediction of targeted therapy in

Journal Article

Protective efficacy of vaccination with NcMIC3 and NcMIC8 against

Taotao ZHANG, Xiao ZHANG, Qun LIU, Jianhai XU, Jing LIU

Journal Article

A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against

PAN Jiangang, ZHOU Xing, CHEN Zhiguang, HAN Ruifa

Journal Article

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han

Journal Article

Clinical efficacy of comprehensive therapy based on traditional Chinese medicine patterns on patients

Journal Article

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal

Journal Article

Experimental study on the efficacy of Fuganling granula on protecting against immunological hepatic injury

Yanli LIU, Rong LIU, Cheng ZHEN, Quanfang GUO, Liping WU, Zhaoxi DING, Yushun BI, Zhiyu LIU

Journal Article

Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes

Journal Article

Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for

Huicong KANG, Xiaoyan LIU, Hu QI, Feng XU, Xiang LI, Yuan WANG, Zhiguang LIU, Suiqiang ZHU

Journal Article

Modified Therapeutic Antibodies: Improving Efficacy

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Journal Article

follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Journal Article